VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

ChemoMetec A/S vs GSK plc

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

GSK plc

GSK · London Stock Exchange

Market cap (USD)$110.5B
Gross margin (TTM)72.5%
Operating margin (TTM)22%
Net margin (TTM)17.5%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryGB
Data as of2025-12-28
Moat score
62/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into GSK plc's moat claims, evidence, and risks.

View GSK analysis

Comparison highlights

  • Moat score gap: ChemoMetec A/S leads (67 / 100 vs 62 / 100 for GSK plc).
  • Segment focus: ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing); GSK plc has 3 segments (37.6% in Specialty Medicines).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: ChemoMetec A/S has 4 moat types across 2 domains; GSK plc has 4 across 3.

Primary market context

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

GSK plc

Specialty Medicines

Market

Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)

Geography

Global

Customer

Hospitals, specialist physicians, payers

Role

Innovator & branded manufacturer

Revenue share

37.6%

Side-by-side metrics

ChemoMetec A/S
GSK plc
Ticker / Exchange
CHEMM - Nasdaq Copenhagen A/S
GSK - London Stock Exchange
Market cap (USD)
n/a
$110.5B
Gross margin (TTM)
n/a
72.5%
Operating margin (TTM)
n/a
22%
Net margin (TTM)
n/a
17.5%
Sector
Healthcare
Healthcare
Industry
n/a
Drug Manufacturers - General
HQ country
DK
GB
Primary segment
Life science research, cell and gene therapy, and bioprocessing
Specialty Medicines
Market structure
Oligopoly
Oligopoly
Market share
15%-25% (estimated)
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
67 / 100
62 / 100
Moat domains
Demand, Network
Supply, Legal, Demand
Last update
2026-04-24
2025-12-28

Moat coverage

Shared moat types

No overlap yet.

ChemoMetec A/S strengths

Installed Base ConsumablesDesign In QualificationInteroperability HubBrand Trust

GSK plc strengths

Capex Knowhow ScaleCompliance AdvantageIP Choke PointSwitching Costs General

Segment mix

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

GSK plc segments

Full profile >

Vaccines

Oligopoly

29.1%

Specialty Medicines

Oligopoly

37.6%

General Medicines

Competitive

33.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.